

Veracyte

Equity Research

December 16, 2013

Price: \$14.00 (12/16/2013) **Price Target: \$16.00**

OUTPERFORM (1)

Doug Schenkel

617.946.3918 doug.schenkel@cowen.com

Shaun Rodriguez, Ph.D.

617.946.3929 shaun.rodriguez@cowen.com

Ji Shi, M.D.

617.946.3922 ji.shi@cowen.com Company Quick Take

Veracyte GEC Receives Positive Coverage Decision From Cigna

The Cowen Insight

VCYT's Afirma GEC received a positive coverage decision from Cigna, expanding total covered lives to >115MM. We believe the announcement is demonstrative of continued momentum towards more covered and eventually contracted lives heading into 2014.


Summary: Today after the close, Veracyate (VCYT – Outperform, \$14.00) announced that Cigna (CI – Outperform/Arnold, \$83.95) issued a positive coverage policy for the company's Afirma Gene Expression Classifier (GEC) test. The new policy applies to ~13MM lives covered by Cigna, effective immediately, and expands the Afirma GEC's total covered lives to >115MM in the US.

The Afirma GEC test is used to reduce the number of unnecessary thyroid surgeries in patients suspected of having thyroid cancer.

Building Momentum Towards More Covered And Contracted Lives

Today's announcement is consistent with previous positive coverage decisions made by several other public and private payers, including Medicare (January 2012), United Healthcare (March 2012), Aetna (June 2013), and Humana (July 2013). We believe these existing coverage decisions, coupled with positive guideline recommendations from the National Comprehensive Cancer Network (NCCN) obtained in January 2013, will help Veracyte to continue to expand GEC coverage and use over the next 12-18 months.

Additional catalysts over the next 12 months include the potential for Veracyte to enter into contracts with one or more payers with existing positive coverage policy. As noted in our initiation report (Link), Veracyte has only entered into contracts with pre-determined test prices with Medicare so far, and entering into similar contracts with private payers will allow those additional volumes to be accrued, therefore increasing revenue predictability and also accelerating revenue growth due to a shift in accounting from cash-based to accrual-based. We believe today's Cigna announcement will help build momentum towards adding contracted lives heading into 2014.



Valuation Methodology

Life Science & Diagnostic Tools:

Price targets are based on several methodologies which may include: analysis of market risk, growth rate, revenue stream, discounted cash flows (DCF), EBITDA, EPS, cash flow (CF), free cash flow (FCF), EV/EBITDA, P/E, PE/growth, P/CF, P/FCF, premium (discount) / average group EV/EBITDA, premium (discount) / average group P/E, sum of the parts, net asset value, dividend returns, and return on equity (ROE) over the next 12 months.

Investment Risks

Life Science & Diagnostic Tools:

Risks to the Medical and Life Science Tools sector may include: reduction or delay in research and development budgets and government funding, reduced or delayed purchasing from health care / hospital customers, increased or extended regulatory hurdles or processes for regulated products, increased dependence on volatile emerging markets for revenues and profitability, and general macroeconomic challenges.


Risks To The Price Target

Risks include but are not limited to: difficulty in expanding payer coverage and entering into payer contracts; reimbursement prices lower than expected; delays or weaker than expected clinical data in support of new products; competition from other potential molecular diagnostic players; weaker than expected uptake in international markets; Genzyme partnership could beomce "relatively" expensive; and delivering on margin / profitability targets.

2

Veracyte

December 16, 2013



Stocks Mentioned In Important Disclosures

Ticker	Company Name
CI	Cigna
VCYT	Veracyte

Analyst Certification

Each author of this research report hereby certifies that (i) the views expressed in the research report accurately reflect his or her personal views about any and all of the subject securities or issuers, and (ii) no part of his or her compensation was, is, or will be related, directly or indirectly, to the specific recommendations or views expressed in this report.

Important Disclosures

Cowen and Company, LLC and or its affiliates make a market in the stock of Veracyte and Cigna securities.

Veracyte has been client(s) of Cowen and Company, LLC in the past 12 months.

Cowen and Company, LLC and/or its affiliates expect to receive, or intend to seek, compensation for investment banking services in the next 3 months from Veracyte.

Veracyte is or was in the past 12 months a client of Cowen and Company, LLC; during the past 12 months, Cowen and Company, LLC provided IB services.

Cowen and Company, LLC and/or its affiliates received in the past 12 months compensation for investment banking services from Veracyte.

Cowen and Company, LLC and/or its affiliates managed or co-managed a public offering of Veracyte within the past twelve months.

Cowen and Company, LLC compensates research analysts for activities and services intended to benefit the firm's investor clients. Individual compensation determinations for research analysts, including the author(s) of this report, are based on a variety of factors, including the overall profitability of the firm and the total revenue derived from all sources, including revenues from investment banking. Cowen and Company, LLC does not compensate research analysts based on specific investment banking transactions.

Disclaimer

This research is for our clients only. Our research is disseminated primarily electronically and, in some cases, in printed form. Research distributed electronically is available simultaneously to all Cowen and Company, LLC clients. All published research can be obtained on the Firm's client website, https://cowenlibrary.bluematrix.com/client/library.jsp.

Further information on any of the above securities may be obtained from our offices. This report is published solely for information purposes, and is not to be construed as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal. Other than disclosures relating to Cowen and Company, LLC, the information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete statement or summary of the available data. Any opinions expressed herein are statements of our judgment on this date and are subject to change without notice.

For important disclosures regarding the companies that are the subject of this research report, please contact Compliance Department, Cowen and Company, LLC, 599 Lexington Avenue, 20th Floor, New York, NY 10022. In addition, the same important disclosures, with the exception of the valuation methods and risks, are available on the Firm's disclosure website at https://cowen.bluematrix.com/sellside/Disclosures.action.

Price Targets: Cowen and Company, LLC assigns price targets on all covered companies unless noted otherwise. The price target for an issuer's stock represents the value that the analyst reasonably expects the stock to reach over a performance period of twelve months. The price targets in this report should be considered in the context of all prior published Cowen and Company, LLC research reports (including the disclosures in any such report or on the Firm's disclosure website), which may or may not include price targets, as well as developments relating to the issuer, its industry and the financial markets. For price target valuation methodology and risks associated with the achievement of any given price target, please see the analyst's research report publishing such targets.

Notice to UK Investors: This publication is produced by Cowen and Company, LLC which is regulated in the United States by FINRA. It is to be communicated only to persons of a kind described in Articles 19 and 49 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005. It must not be further transmitted to any other person without our consent.

Copyright, User Agreement and other general information related to this report

© 2013 Cowen and Company, LLC. Member NYSE, FINRA and SIPC. All rights reserved. This research report is prepared for the exclusive use of Cowen clients and may not be reproduced, displayed, modified, distributed, transmitted or disclosed, in whole or in part, or in any form or manner, to others outside your organization without the express prior written consent of Cowen. Cowen research reports are distributed simultaneously to all clients eligible to receive such research reports. Any unauthorized use or disclosure is prohibited. Receipt and/or review of this research constitutes your agreement not to reproduce, display, modify, distribute, transmit, or disclose to others outside your organization the contents, opinions, conclusion, or information contained in this report (including any investment recommendations, estimates or price targets). All Cowen trademarks displayed in this report are owned by Cowen and may not be used without its prior written consent.

Cowen and Company, LLC. New York (646) 562-1000 Boston (617) 946-3700 San Francisco (415) 646-7200 Chicago (312) 577-2240 Cleveland (440) 331-3531 Atlanta (866) 544-7009 London (affiliate) 44-207-071-7500

COWEN AND COMPANY RATING DEFINITIONS

Cowen and Company Rating System effective May 25, 2013

Outperform (1): The stock is expected to achieve a total positive return of at least 15% over the next 12 months

Market Perform (2): The stock is expected to have a total return that falls between the parameters of an Outperform and Underperform over the next 12 months

Underperform (3): Stock is expected to achieve a total negative return of at least 10% over the next 12 months

Assumption: The expected total return calculation includes anticipated dividend yield

Cowen and Company Rating System until May 25, 2013

Outperform (1): Stock expected to outperform the S&P 500

Neutral (2): Stock expected to perform in line with the S&P 500

Underperform (3): Stock expected to underperform the S&P 500

 $\textbf{Assumptions:} \ \mathsf{Time} \ \mathsf{horizon} \ \mathsf{is} \ \mathsf{12} \ \mathsf{months}; \ \mathsf{S\&P} \ \mathsf{500} \ \mathsf{is} \ \mathsf{flat} \ \mathsf{over} \ \mathsf{forecast} \ \mathsf{period}$

Cowen Securities, formerly known as Dahlman Rose & Company, Rating System until May 25, 2013

www.cowen.com 3

December 16, 2013

Buy – The fundamentals/valuations of the subject company are improving and the investment return is expected to be 5 to 15 percentage points higher than the general market return

Sell – The fundamentals/valuations of the subject company are deteriorating and the investment return is expected to be 5 to 15 percentage points lower than the general market return

Hold – The fundamentals/valuations of the subject company are neither improving nor deteriorating and the investment return is expected to be in line with the general market return

Cowen And Company Rating Definitions

Distribution of Ratings/Investment Banking Services (IB) as of 09/30/13


Rating	Count	Ratings Distribution	Count	IB Services/Past 12 Months
Buy (a)	394	58.72%	54	13.71%
Hold (b)	255	38.00%	5	1.96%
Sell (c)	22	3.28%	1	4.55%

(a) Corresponds to "Outperform" rated stocks as defined in Cowen and Company, LLC's rating definitions. (b) Corresponds to "Market Perform" as defined in Cowen and Company, LLC's ratings definitions. (c) Corresponds to "Underperform" as defined in Cowen and Company, LLC's ratings definitions.

Note: "Buy", "Hold" and "Sell" are not terms that Cowen and Company, LLC uses in its ratings system and should not be construed as investment options. Rather, these ratings terms are used illustratively to comply with FINRA and NYSE regulations.

Veracyte Rating History as of 12/13/2013

powered by: BlueMatrix



Closing Price Target Price

Cigna Rating History as of 12/13/2013

powered by: BlueMatrix



Legend for Price Chart:

I = Initation | 1 = Outperform | 2 = Market Perform | 3 = Underperform | UR = Price Target Under Review | T = Terminated Coverage | \$xx = Price Target | NA = Not Available

Veracyte

December 16, 2013

Points Of Contact

Reaching Cowen

Main U.S. Locations

New York

599 Lexington Avenue New York, NY 10022 646.562.1000 800.221.5616

Atlanta

3399 Peachtree Road NE Suite 417 Atlanta, GA 30326 866.544.7009

Boston

Two International Place Boston, MA 02110 617.946.3700 800.343.7068

Cleveland

20006 Detroit Road Suite 100 Rocky River, OH 44116 440.331.3531

San Francisco

555 California Street, 5th Floor San Francisco, CA 94104 415.646.7200 800.858.9316

Chicago

181 West Madison Street Suite 1925 Chicago, IL 60602 312.577.2240

International Locations

Cowen International Limited

London

1 Snowden Street - 11th Floor London EC2A 2DQ **United Kingdom** 44.20.7071.7500

Cowen and Company (Asia) Limited

Hong Kong

Suite 1401 Henley Building No. 5 Queens Road Central Central, Hong Kong 852 3752 2333





